Due to rising antimicrobial resistance, the treatment of complicated UTIs and acute pyelonephritis is becoming more difficult ...

Digital and virtual channels make B2B sales more efficient—but they can also make relationships brittle. When stakes are high ...

GSK & Spero announce positive PIVOT-PO phase III trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections: London, UK Wednesday, October ...

New data presented at IDWeek 2025 by Japanese drugmaker Shionogi highlight the real-world effectiveness of cefiderocol in ...

Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...

Investing.com -- Spero Therapeutics (NASDAQ:SPRO) stock rose 7% on Tuesday after the company and partner GSK (NYSE:GSK) announced positive Phase 3 trial results for tebipenem HBr, a potential first-in ...

Our Management Tip of the Day newsletter continues to be one of HBR’s most popular newsletters. In this article, we’ve ...

GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...

In addition, GSK and Nasdaq-listed Spero Therapeutics Inc announced positive Pivot-PO phase III data which showed tebipenem HBr's potential as the first oral carbapenem antibiotic for patients with ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK and Spero Therapeutics announced promising results from the phase III PIVOT-PO trial ...

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of ...

Harbour Energy ( ($GB:HBR) ) has shared an update. Harbour Energy plc announced that dividends paid on shares held by a person discharging ...